GLP-1 Medications: The Most Important Shift in Weight Loss Medicine in a Generation
The emergence of GLP-1 receptor agonists has fundamentally changed the clinical conversation around obesity and metabolic health. For decades, the standard approach to weight management placed responsibility almost entirely on patients — eat less, move more, try harder. GLP-1 medications have reframed the discussion by addressing what was always a biological challenge with a biological solution.
What are GLP-1 medications?
GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the gut in response to eating. GLP-1 receptor agonists — including semaglutide and tirzepatide — are medications that mimic and extend this hormone's effects, producing sustained appetite regulation and metabolic support. Originally developed for type 2 diabetes management, these medications revealed a remarkable secondary effect: significant, sustained weight loss. Clinical trials have shown average weight loss of 10–20%+ of body weight — outcomes that far exceed what any previous medication class had demonstrated.
Why this represents a paradigm shift
Before GLP-1 medications, pharmaceutical weight loss options were limited, often poorly tolerated, and produced modest results. The clinical community struggled to offer patients anything that meaningfully closed the gap between lifestyle intervention and bariatric surgery. GLP-1 medications change that equation. They work by reducing the constant hunger and food preoccupation — often called 'food noise' — that makes sustained caloric restriction so difficult, slowing gastric emptying to extend feelings of fullness, improving insulin sensitivity and blood sugar regulation, reducing systemic inflammation and cardiovascular risk markers, and supporting metabolic function independently of weight change.
The clinical evidence
The evidence base for GLP-1 medications is extensive and growing. The STEP trials (semaglutide) showed average weight loss of ~15% over 68 weeks in non-diabetic adults with obesity. The SURMOUNT trials (tirzepatide) showed average weight loss of up to 22.5% over 72 weeks — the highest efficacy demonstrated by any weight loss medication in clinical trials. The SELECT trial (semaglutide) found a 20% reduction in major adverse cardiovascular events in non-diabetic adults with obesity and existing cardiovascular disease. And the LEADER trial (semaglutide) showed significant reductions in cardiovascular mortality, non-fatal heart attack, and non-fatal stroke in patients with type 2 diabetes.
Who is a candidate for GLP-1 treatment?
GLP-1 medications are generally indicated for adults with a BMI of 30 or higher (obesity), or a BMI of 27 or higher with at least one weight-related health condition — such as type 2 diabetes, hypertension, high cholesterol, or sleep apnea. Candidacy is determined by a licensed provider through a full medical history review.
The access challenge
Despite the clinical evidence, access to GLP-1 medications has been uneven. Insurance coverage remains inconsistent — many plans cover these medications for type 2 diabetes but exclude them for weight management. This is where telehealth-first models have become important. HolaVida Health offers direct-pay GLP-1 programs that make treatment accessible without insurance complexity.
Responsible GLP-1 care: what it requires
The clinical promise of GLP-1 medications is real — but so is the importance of appropriate medical oversight. Responsible GLP-1 care includes a full medical history review and eligibility assessment before prescribing, gradual dose escalation to minimize side effects, ongoing monitoring of progress, side effects, and relevant health markers, integration of nutritional and behavioral coaching alongside medication, and clear guidance on long-term management and what happens if treatment is discontinued.
HolaVida Health's GLP-1 program
HolaVida Health provides licensed, provider-guided GLP-1 treatment through a fully virtual model — with transparent pricing, ongoing medical oversight, and integrated coaching support in English and Spanish. Semaglutide is $129/month (quarterly) or $133/month (month-to-month), and tirzepatide is $190/month (quarterly) or $200/month (month-to-month), with prescription and coaching included. Our approach is grounded in clinical evidence, built for accessibility, and designed for the long term.
Ready to get personalized care?
Talk with a HolaVida Health clinician in your preferred language and get a plan built around you.
Learn more